Journal article · 2025 · Open access
ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO
Annals of the Rheumatic Diseases, 84, 1508–1509 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.06.867
In brief
“ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO” is a 2025 journal article by J. Wang, published in Annals of the Rheumatic Diseases. OpenAlex counts 2 citations as of 20 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.
- Citations
- 2
- Most cited in
- 2025 (1)
- Authors
- 1
Abstract
Background: B cell depletion therapies targeting CD19 or BCMA, including Chimeric antigen receptor T-cell (CAR-T) therapies and Bispecific antibody such as blinatumomab and Teclistamab, had shown impressive efficacy in treating B cell malignancy. In the last few years, those therapies also showed great potential in the treatment of systemic lups erythematosus (SLE), Rheumatoid arthritis (RA), and other autoimmune diseases by inducing deep B cell depletion, and potentially repopulating and resetting the B cell population and immunoglobins, and long-lasting clinical responses in otherwise hard to treat autoimmune diseases. However, challenges exist for these therapies such as significant safety risks and logistical challenges. Objectives: Development of a novel IgG-like CD19XBCMAXCD3 T cell engager to target broad B cell populations. Methods: By antibody engineering, KT501, a novel IgG-like CD19XBCMAXCD3 T cell engager, was developed. Results: KT501 exhibited potent B cell killing in healthy and SLE patient PBMC. In cynomolgus monkeys, KT501 induced rapid and deep B-cell depletion in a dose responsive manner. At 0.01mg/kg, quick and deep depletion of B cells was observed but quickly rebound at day 21. At 0.1mg/kg, deep B cell depletion in peripheral blood, bone marrow and lymph nodes were observed even at day 21. At 1mg/kg, minimal cytokine releases were observed with deep B cell depletion. Conclusion: Those preclinical data strongly support clinical development of KT501 in autoimmune disease treatment, which is expected to move into Phase I trial in Q4, 2025. REFERENCES: [1] Müller F, etal. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024 Feb 22;390(8):687-700. [2] Bucci L, etal. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024 Jun;30(6):1593-1601. [3] Alexander T, etal. Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2024 Sep 5;391(9):864-866. Acknowledgements: NIL . Disclosure of Interests: John Wang I'm a shareholder of Kalitherapeutics, I'm employed by Kalitherapeutics. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Wang, J. (2025). ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO. Annals of the Rheumatic Diseases, 84, 1508–1509. https://doi.org/10.1016/j.ard.2025.06.867
MLA 9
Wang, J. “ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO.” Annals of the Rheumatic Diseases, vol. 84, 2025, pp. 1508–1509. https://doi.org/10.1016/j.ard.2025.06.867.
Chicago
Wang, J. 2025. “ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO.” Annals of the Rheumatic Diseases 84: 1508–1509. https://doi.org/10.1016/j.ard.2025.06.867.
Harvard
Wang, J. (2025) ‘ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO’, Annals of the Rheumatic Diseases, 84, pp. 1508–1509. doi:10.1016/j.ard.2025.06.867.
IEEE
J. Wang, “ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO,” Annals of the Rheumatic Diseases, vol. 84, pp. 1508–1509, 2025, doi: 10.1016/j.ard.2025.06.867.
BibTeX
@article{wang2025bcma,
title = {{ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO}},
author = {Wang, J.},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
pages = {1508--1509},
doi = {10.1016/j.ard.2025.06.867},
url = {https://doi.org/10.1016/j.ard.2025.06.867}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- CD19
- BCMA
- T-cell engagers
- bispecific antibodies
- B-cell depletion
- autoimmune disease
- systemic lupus erythematosus
- rheumatoid arthritis
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Wang, J. (2025). ABS0200 KT501, A CD19, BCMA-DIRECTED T-CELL ENGAGER (TCE), LEADS TO DEEP B-CELL DEPLETION AND MINIMAL CYTOKINE RELEASE IN VIVO. Annals of the Rheumatic Diseases, 84, 1508–1509. https://doi.org/10.1016/j.ard.2025.06.867
How many times has this paper been cited?
2 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.
Who wrote this paper?
J. Wang.
What is the DOI of this paper?
10.1016/j.ard.2025.06.867, permanently at https://doi.org/10.1016/j.ard.2025.06.867. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.